APVO
Aptevo Therapeutics·NASDAQ
--
--(--)
--
--(--)
1.70 / 10
Underperform
Comprehensive analysis: poor fundamentals (1.7/10). Positive dimensions: Fixed assets turnover ratio and Inventory turnover ratio, balanced by issues in Net profit / Total profit (%) and Current assets turnover ratio. Resulting position: selective.
Analysis Checks(3/5)
Inventory turnover ratio
Value53.31
Score2/3
Weight163.36%
1M Return-2.63%
Value53.31
Score2/3
Weight163.36%
1M Return-2.63%
Current assets turnover ratio
Value2.27
Score1/3
Weight32.46%
1M Return-0.48%
Value2.27
Score1/3
Weight32.46%
1M Return-0.48%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Gross profit margin (%)
Value35.84
Score2/3
Weight-106.48%
1M Return1.47%
Value35.84
Score2/3
Weight-106.48%
1M Return1.47%
Fixed assets turnover ratio
Value1827.00
Score2/3
Weight-8.39%
1M Return0.12%
Value1827.00
Score2/3
Weight-8.39%
1M Return0.12%
Inventory turnover ratio
Value53.31
Score2/3
Weight163.36%
1M Return-2.63%
Value53.31
Score2/3
Weight163.36%
1M Return-2.63%
Gross profit margin (%)
Value35.84
Score2/3
Weight-106.48%
1M Return1.47%
Value35.84
Score2/3
Weight-106.48%
1M Return1.47%
Current assets turnover ratio
Value2.27
Score1/3
Weight32.46%
1M Return-0.48%
Value2.27
Score1/3
Weight32.46%
1M Return-0.48%
Fixed assets turnover ratio
Value1827.00
Score2/3
Weight-8.39%
1M Return0.12%
Value1827.00
Score2/3
Weight-8.39%
1M Return0.12%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Value100.00
Score0/3
Weight19.05%
1M Return-0.30%
Is APVO fundamentally strong?
- APVO scores 1.70/10 on fundamentals and holds a Premium valuation at present. Backed by its -195.42% ROE, 0.00% net margin, -0.28 P/E ratio, 0.38 P/B ratio, and 123.10% earnings growth, these metrics solidify its Underperform investment rating.
